Results 91 to 100 of about 10,352 (222)

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

Allergy, EarlyView.
This study performed an unbiased molecular profiling of CHE patients across diverse etiologies to identify shared pathogenic drivers and evaluate the impact of IL‐4Rα blockade via dupilumab over 16 weeks. CHE shows a mixed immune signature involving type 1, 2, and 3 pathways with features of atopic dermatitis and psoriasis.
Perrine Gery, Rüçhan Ekren, Emilie Bérard, Aurélie Du‐Thanh, Hugo Rimet, Fatma Jendoubi, Vanina Lenief, Nadia Raison‐Peyron, Amel Bouznad, Maria P. Konstantinou, Jonathan Rioual, Lilian Basso, Juliette Mouiren, Manon Boussier, Brigitte Milpied, Cristina Bulai Livideanu, Louise Jaulent, Florence Hacard, Marine A. Lefevre, Audrey Nosbaum, Julien Seneschal, Marc Vocanson, Carle Paul, Nicolas Gaudenzio, Marie Tauber, on behalf of the French Atopic Dermatitis Network from de GREAT Research group   +25 more
wiley   +1 more source

Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison

Dermatology and Therapy
Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 
Sonja Ständer, Andreas Pinter, Firas G. Hougeir, Patricia Guyot, Yingxin Xu, Amy H. Praestgaard, Nick Freemantle, Ana B. Rossi, Gaëlle Bégo-Le-Bagousse, Zhixiao Wang, Kerry Noonan, Mike Bastian   +11 more
doaj   +1 more source

Dupilumab as an Effective Adjuvant Therapy for Corticosteroid‐Refractory Lichenoid‐Bullous Dermatitis Secondary to Pembrolizumab

Australasian Journal of Dermatology, EarlyView.
Brandon Tan, Gaurav N. Pathak, Alexis Lara Rivero   +2 more
wiley   +1 more source

Type‐2‐Inflammatory‐Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade

Allergy, EarlyView.
Studies suggest that type 2 inflammatory diseases are driven by overactivation of the IL4/IL13 pathway, manifesting differently in distinct tissues. We performed quantitative analyses using several large independent datasets to explore the interrelation of type 2 inflammatory diseases based on co‐prevalence, genetic predispositions, and transcriptomic ...
Jennifer D. Hamilton, Manuel A. R. Ferreira, Wei Keat Lim, Carlo Sidore, Matthew F. Wipperman, Wenzhen Ge, Xue Song, Changming Xia, Julie E. Horowitz, Andrea T. Hooper, Sara C. Hamon, Jennifer Maloney, Jamie M. Orengo, Zhen Chen, Stephanie Amato Ricci, Bolanle Akinlade, Aris Baras, Gary Herman, Brandy L. Bennett, George D. Yancopoulos   +19 more
wiley   +1 more source

Is Asthma Remission a New Achievable Goal? A Review of the Current Drug‐Related Evidence and Predictors

Allergy, EarlyView.
ABSTRACT Advances in asthma therapies have shown that clinical remission may be an achievable therapeutic goal for patients with asthma. This review discusses the current definitions of remission in asthma, the predictors of remission, airway inflammation/epithelial damage in asthma remission, airway remodeling, paradigms in defining remission and ...
Fatma Esra Gunaydin, Giulia Marcassa, Bianca Olivieri, Gianenrico Senna, Marco Caminati   +4 more
wiley   +1 more source

Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma

Allergy, EarlyView.
EXPEDITION (NCT02573233) assessed the effects of dupilumab on airway inflammation in patients with persistent asthma using bronchoscopy and gene expression analysis. Dupilumab showed no appreciable effect on inflammatory cell types in biopsies or BALF samples.
Michael E. Wechsler, Sally E. Wenzel, Steve D. Groshong, Mario Castro, Ian D. Pavord, Klaus F. Rabe, Elizabeth Laws, Alexandre Jagerschmidt, Kaitlyn Gayvert, Sivan Harel, Jennifer D. Hamilton, Nikhil Amin, Lu Zhang, Heming Xing, Anissa Elfakir, Bema Coulibaly, Souâd Naimi, Sara Hamon, Paul J. Rowe, Frank Nestle, Danen M. Cunoosamy, Emanuele de Rinaldis, Leda P. Mannent   +22 more
wiley   +1 more source

Development of Nummular Dermatitis Following Dupilumab Therapy Suggests a Th17‐Driven Mechanism

Australasian Journal of Dermatology, EarlyView.
Olga Pawlik, Michelle McRae
wiley   +1 more source

Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo‐Controlled, Phase III Trial

Allergy, EarlyView.
Dupilumab significantly improved nasal polyp score, nasal congestion, olfaction, total symptom score, and disease‐specific quality of life in Chinese patients with uncontrolled CRSwNP. Incidence of treatment‐emergent adverse events was similar between dupilumab and placebo.
Mu Xian, Menglin Wang, Changqing Zhao, Lijia Wan, Yu Xu, Juan Meng, Rui Xu, Xicheng Song, Li Shi, Yucheng Yang, Yan Jiang, Yanzhen Wu, Bethany Ling, Vivian Li, Andrew P. Fontenot, Lacey R. Robinson, Neelam A. Phadke, Chengshuo Wang, Luo Zhang   +18 more
wiley   +1 more source

Remission in Global Airway Diseases: EUFOREA Consensus Paper

Allergy, EarlyView.
ABSTRACT The therapeutic goal in chronic airway diseases is shifting from symptom control to disease remission. Disease‐modifying therapies, including biologics and allergen immunotherapy, have made remission achievable in patients with severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), or allergic rhinitis (AR).
J. Christian Virchow, Xander Bertels, Vibeke Backer, Benjamin S. Bleier, Marco Caminati, Diego M. Conti, Eugenio De Corso, Mina Gaga, Valerie J. Lund, Corrado Pelaia, Anju T. Peters, Glenis K. Scadding, Martin Wagenmann, Riyad O. Al‐Lehebi, Guy G. Brusselle, Philippe Gevaert, Liam G. Heaney, Stella E. Lee, Florence Schleich, Frederik Trinkmann, Peter W. Hellings, Wytske J. Fokkens, Paola Rogliani   +22 more
wiley   +1 more source

Differential Roles for IL‐4Rα and IL‐13Rα1 in Immune Cell Infiltration and Epithelial Remodeling in Experimental Eosinophilic Gastritis

Allergy, EarlyView.
This study described the development of an experimental model for eosinophilic gastritis (EoG). Experimental EoG recapitulates histopathological features of human disease. including foveolar elongation, fibrosis, eosinophilia, mastocytosis and shared transcriptional programs.
Anish Dsilva, Shraddha Sharma, Shireen Barakey, Ariel Wagner, Alice Keisar, Tali Bar‐on, Michal Itan, Ariel Munitz   +7 more
wiley   +1 more source